Skip to Content
Merck
CN

QVHLSET

Sigma-Aldrich

QuicTPD VHL ligand set

new
Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

NACRES:
NA.21
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

packaging

pkg of 50 mg

Quality Level

storage temp.

2-8°C

General description

(S,R,S)-AHPC and (S,R,S)-AHPC-Me are recruiters of von-Hippel-Lindau (VHL) protein that can be leveraged for targeted protein degradation research. They are provided at 50 mg each.

Application

Useful for construction of VHL based partial protacs of full protacs, by utilizing the amine terminus to add suitable linkers with peptide coupling reactions. These can also be used as controls/competitors to confirm target engagement of putative protacs.

Features and Benefits

Quantities provided are sufficient to do atleast 96 reactions at 1 micromole each with a D2B approach with a library of suitable bifunctional linkers ending in carboxylic acid terminus to generate a library of partial protacs or full protacs.

Other Notes

VHL Ligand Set part of QuicTPD kit

Legal Information

QuicTPD is a trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Regulatory Information

新产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Xin Han et al.
Journal of medicinal chemistry, 62(2), 941-964 (2019-01-11)
We report herein the discovery of highly potent PROTAC degraders of androgen receptor (AR), as exemplified by compound 34 (ARD-69). ARD-69 induces degradation of AR protein in AR-positive prostate cancer cell lines in a dose- and time-dependent manner. ARD-69 achieves
Ashton C Lai et al.
Angewandte Chemie (International ed. in English), 55(2), 807-810 (2015-11-26)
Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs. PROTAC technology employs small molecules that recruit target proteins for ubiquitination and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service